Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease
Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with radiation therapy alone in treating patients with early-stage Hodgkin's disease.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES: I. Determine the recurrence rate and long term survival of patients with early stage Hodgkin's disease given vincristine/doxorubicin/prednisolone/ etoposide/cyclophosphamide/bleomycin (VAPEC-B) chemotherapy and involved field radiation vs mantle radiotherapy.
OUTLINE: This is a randomized multicenter study. Patients are randomized to receive either vincristine/doxorubicin/prednisolone/etoposide/cyclophosphamide/ bleomycin (VAPEC-B) chemotherapy and involved field radiotherapy or mantle radiotherapy only. Patients receiving VAPEC-B are given prednisolone daily on weeks 1-6, doxorubicin IV along with cyclophosphamide IV on week 1, doxorubicin IV and etoposide orally for 5 days on week 3, and vincristine and bleomycin IV on weeks 2 and 4. Involved field radiotherapy is commenced at week 6, within 14 to 21 days of the last chemotherapy treatment. Patients randomized to receive mantle radiotherapy only are given treatments daily for 4 weeks. Patients are followed every 3 months for the first two years, every 4 months for the third year, every 6 months for the fourth and fifth years and annually thereafter.
PROJECTED ACCRUAL: 400 patients will be accrued over 4-5 years.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Preston, Det Forenede Kongerige, PR2 9HT
- Royal Preston Hospital
-
-
England
-
Birmingham, England, Det Forenede Kongerige, B15 2TT
- University Birmingham
-
Bristol, England, Det Forenede Kongerige, BS2 8ED
- Bristol Oncology Centre
-
Bristol, England, Det Forenede Kongerige, BS2 8BJ
- Bristol Royal Hospital for Sick Children
-
Cambridge, England, Det Forenede Kongerige, CB2 2QQ
- Addenbrooke's NHS Trust
-
Derby, England, Det Forenede Kongerige, DE1 2QY
- Derbyshire Royal Infirmary
-
Leeds, England, Det Forenede Kongerige, LS16 6QB
- Cookridge Hospital
-
Leicester, England, Det Forenede Kongerige, LE1 5WW
- University Hospitals of Leicester
-
London, England, Det Forenede Kongerige, W1G 3AA
- Middlesex Hospital- Meyerstein Institute
-
Merseyside, England, Det Forenede Kongerige, L63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne, England, Det Forenede Kongerige, NE4 6BE
- Newcastle General Hospital
-
Northwood, England, Det Forenede Kongerige, HA6 2RN
- Mount Vernon Hospital
-
Norwich, England, Det Forenede Kongerige, NR1 3SR
- Norfolk & Norwich Hospital
-
Oxford, England, Det Forenede Kongerige, 0X3 9DU
- Oxford Radcliffe Hospital
-
Sutton, England, Det Forenede Kongerige, SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea, England, Det Forenede Kongerige
- Southend General Hospital
-
-
Scotland
-
Edinburgh, Scotland, Det Forenede Kongerige
- Royal Hospital for Sick Children
-
-
-
-
-
Cape Town, Sydafrika, 7925
- Groote Schuur Hospital, Cape Town
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS: Histologically proven stage IA or IIA Hodgkin's disease without mediastinal bulk Patients with Hodgkin's disease existing below diaphragm only are not eligible
PATIENT CHARACTERISTICS: Age: 16 to 75 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not HIV positive No prior malignancy other than basal cell carcinoma or cervical intraepithelial neoplasia
PRIOR CONCURRENT THERAPY: No prior treatment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studiestol: Michael Williams, MD, Cambridge University Hospitals NHS Foundation Trust
Publikationer og nyttige links
Generelle publikationer
- Radford JA, Williams MV, Hancock BW, et al.: Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial. [Abstract] Eur J Haematol 73 (Suppl 65): A-E08, 39, 2004.
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Lymfom
- Hodgkins sygdom
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Anti-inflammatoriske midler
- Antirheumatiske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Antineoplastiske midler, fytogene
- Topoisomerase II-hæmmere
- Topoisomerasehæmmere
- Antibiotika, antineoplastisk
- Prednisolon
- Cyclofosfamid
- Etoposid
- Doxorubicin
- Liposomal doxorubicin
- Vincristine
- Bleomycin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CDR0000065522
- MRC-UKLG-LY07
- EU-97004
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .